Literature DB >> 19285751

Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments.

Jan P van Meerbeeck1, Veerle F M Surmont.   

Abstract

Few issues are as controversial in non-small cell lung cancer as the management of patients with stage IIIA-N2 non-small cell lung cancer. This manuscript reviews the reasons and the biases inherent to this controversy and discusses the different treatment approaches with emphasis on survival as evidenced by meta-analyses and large randomised clinical trials. Prospects on novel treatment modalities and future research opportunities are presented.

Entities:  

Mesh：

Year:  2009        PMID： 19285751     DOI： 10.1016/j.lungcan.2009.02.007

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  9 in total

1.  Does pneumonectomy have a role in the treatment of stage IIIA non-small cell lung cancer?

Authors:  Asad A Shah; Mathias Worni; Christopher R Kelsey; Mark W Onaitis; Thomas A D'Amico; Mark F Berry
Journal:  Ann Thorac Surg       Date:  2013-03-29       Impact factor: 4.330

2.  Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer.

Authors:  Na Li; Lu Han; Hui Jing
Journal:  Exp Ther Med       Date:  2017-08-16       Impact factor: 2.447

3.  The optimal chemotherapy for stage III non-small cell lung cancer patients.

Authors:  Shirish M Gadgeel
Journal:  Curr Oncol Rep       Date:  2011-08       Impact factor: 5.075

Review 4.  Emerging developments of chemoradiotherapy in stage III NSCLC.

Authors:  Allan Price
Journal:  Nat Rev Clin Oncol       Date:  2012-08-28       Impact factor: 66.675

5.  The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience.

Authors:  Joaquim Bosch-Barrera; Carlos García-Franco; Francisco Guillén-Grima; Marta Moreno-Jiménez; José María López-Picazo; Alfonso Gúrpide; José Luis Pérez-Gracia; Javier Aristu; Wenceslao Torre; Jesús García-Foncillas; Ignacio Gil-Bazo
Journal:  Clin Transl Oncol       Date:  2012-07-20       Impact factor: 3.405

6.  Therapeutic effects of lenvatinib in combination with rAd-p53 for the treatment of non-small cell lung cancer.

Authors:  Renzhi Yu; Minghuan Wang; Xiuli Zhu; Zhe Sun; Aiying Jiang; Huixin Yao
Journal:  Oncol Lett       Date:  2018-09-11       Impact factor: 2.967

7.  Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series.

Authors:  Shao Feng; Zhang Qiang; Cheng Wanwan; Zeng Zhaozhun; Xie Yuewu; Fang Shencun
Journal:  Front Oncol       Date:  2022-03-29       Impact factor: 6.244

8.  Combined radio- and chemotherapy for non-small cell lung cancer: systematic review of landmark studies based on acquired citations.

Authors:  Carsten Nieder; Adam Pawinski; Nicolaus H Andratschke
Journal:  Front Oncol       Date:  2013-07-09       Impact factor: 6.244

9.  Evaluation of new classifications of N descriptor in non-small cell lung cancer (NSCLC) based on the number and the ratio of metastatic lymph nodes.

Authors:  Konrad Pawełczyk; Marek Marciniak; Piotr Błasiak
Journal:  J Cardiothorac Surg       Date:  2016-04-14       Impact factor: 1.637
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.